Alcresta Therapeutics, Inc.

Alcresta develops rare disease, enzyme-based products helping to address fat malabsorption in patients who are enterally fed at home or in the hospital. Our RELiZORB® (immobilized lipase) is indicated for use in pediatric patients (ages 2+) and adult patients to hydrolyze fats in enteral formula. Please see Instructions for Use at wwww.relizorb.com.